Development Funding. (a) Viewray will pay 3D Line the then U.S. Dollar equivalent of €[***] within three (3) days of the Effective Date for the engineering services required to develop/ deliver the Deliverable described in Section 2.1(a)(i).
Development Funding. 41 4.7 Development in the ROW ................................................... 43 4.8
Development Funding. The Union shall, through its national benefits staff, arrange for research and staff support to the parties to support the joint effort of the parties to develop this new model of retirement benefits.
Development Funding. The Employer shall make a grant of seventy-five thousand dollars ($75,000) to fund the infrastructure of the Trust on July 1, 2017.
Development Funding. 1. New Product Programs that are approved by the Advisory Board shall be funded as follows:
Development Funding. Consideration received from a Sublicensee of AgeX that is explicitly designated in the sublicense agreement to cover Development Costs will not be considered Sublicensing Considering subject to Section 2.2(d) (iii). Any Sublicensing Considering actually received by AgeX that was designated as Development Costs that were not actually incurred by AgeX as Development Costs in respect to Development of a Licensed Product, Licensed Service or Licensed Process, will become Sublicensing Consideration if not returned upon completion or termination of the project for which the consideration was so designated.
Development Funding. GSK shall, subject to the remainder of this Section 4.5, compensate CureVac for the Development Costs CureVac incurs performing the Development activities set forth in each R&D Plan (with FTE calculated at the FTE Rate) in accordance with the budget and assumptions as agreed under that R&D Plan. The Parties shall in good faith consider means of gaining efficiencies in the performance of the R&D Plans that have a positive impact on the associated budget, such as outsourcing of certain research activities to a subcontractor. The compensation is to be paid by GSK to CureVac on a Calendar Quarterly basis. GSK shall make payments to CureVac within [*****] after receipt of an invoice from CureVac, which CureVac shall provide on a Calendar Quarterly basis, with supportive documentation reasonably detailing the composition of the agreed budgeted cost (with FTE calculated at the FTE Rate) for the applicable Calendar Quarter period. CureVac shall notify GSK as soon as reasonably practicable in the event that it becomes aware that Development Costs are expected to deviate from the amounts approved in the Development budget, as a result of a change to the assumptions under the R&D Plan, whereupon the Parties shall discuss the causes of such deviation and evaluate potential mitigation measures relating thereto, and an appropriate adjustment (if any) to the Development budget. The Parties shall refer any Development budget increase amounting to greater than [*****] of the previously approved amount to the JSC for prior approval. Unless such budget increase is approved by the JSC, GSK shall not be liable to compensate any amounts to CureVac in excess of [*****] of the amount set out in the agreed Development budget from time to time. GSK shall not unreasonably withhold its approval to any budget increase which is reasonably required as a result of the change to a budgeting assumption set out in a R&D Plan.
Development Funding. According to Section 4, Amylin will pay to ACTII the FTE Hourly Rate for all work performed by ACTII under the Product Development Plan.
Development Funding. Tigercat will use [***] it receives under the Equity Agreements (the “Development Funding”) to fund the Development of Licensed Compounds and Licensed Products in accordance with the Development Plan. For the avoidance of doubt, amounts paid by Tigercat to VPD under the Services Agreement to design and manage the Development of the Licensed Compounds and Licensed Products shall be deemed to have been used to fund the Development of Licensed Compounds and Products in accordance with the Development Plan.
Development Funding. 12A.1 Subject to the terms of this Section 12A.1, development funding for Products which USSC may in its sole discretion desire to have developed by Misonix hereunder ("Development Funding") shall be at the cost of USSC. Prior to Misonix incurring any Development Funding costs or expenses, Misonix shall notify USSC in writing of the proposed project and proposed expenditures in reasonable detail and USSC shall have a period of ten business days within which to approve or reject the same, in writing, in USSC's sole discretion. If such proposed expenditures are approved by USSC, the acceptance by USSC shall be accompanied by a check to Misonix in the approved amount of the agreed upon Development Funding. If such proposed expenditures are rejected, such rejection shall be reasonably detailed. Misonix shall maintain books and records concerning Development Funding during the term of this Agreement and for five (5) years thereafter. USSC and its representatives shall have the right to review such books and records during normal business hours upon prior notice. Nothing hereinabove in this Section 12A.1 commits USSC to any Development Funding or prohibit or limit USSC from engaging in development of Products by itself or with any third party at the cost of USSC.
